Ph.D., VP Global Head Viral Vaccine Discovery & Translational Medicine and Disease Area Stronghold Leader Viral Vaccines, Janssen Vaccines & Prevention B.V.; Professor in Virology, Amsterdam University Medical Center
Biography
Hanneke Schuitemaker, Ph.D., is the Head of Viral Vaccine Discovery and Translational Medicine and Disease Area Stronghold Leader for Viral Vaccines at Janssen Vaccines & Prevention B.V. In this role, she oversees Janssen’s viral vaccine programs including investigational vaccine candidates for HIV, respiratory syncytial virus (RSV), Ebola, Zika, COVID-2019 and HPV. In addition, she is a Professor of Virology at the Amsterdam University Medical Center (since 2004). Hanneke Schuitemaker is a medical biologist by training, received her Ph.D. in Medicine in 1992 at the University of Amsterdam and worked for more than 20 years on HIV-1 pathogenesis, first at Sanquin (1989-2007), the blood supply foundation in the Netherlands, where she was the Chair of the department of Clinical Viro-Immunology (1998-2007), and then at the Amsterdam University Medical Center (2008-2010), where she was the Chair of the Department of Experimental Immunology and a member of the Research Council. From mid-2003 to mid-2004, she worked as a visiting scientist at The Scripps Research Institute in La Jolla, California. She successfully trained more than 30 Ph.D. students and co-authored close to 300 peer-reviewed scientific articles.
Talk
The Development of Janssen’s COVID-19 vaccine
Janssen is developing a COVID-19 vaccine that is based on its proprietary Adeno virus 26 vector now encoding an optimized SARS-CoV-2 Spike protein. An update on preclinical data and progress of clinical development will be given.
